Hennion & Walsh Asset Management Inc. Buys 10,532 Shares of Boston Scientific Co. (NYSE:BSX)

Hennion & Walsh Asset Management Inc. grew its stake in Boston Scientific Co. (NYSE:BSX) by 15.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 77,216 shares of the medical equipment provider’s stock after acquiring an additional 10,532 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Boston Scientific were worth $5,289,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. AMF Tjanstepension AB lifted its holdings in shares of Boston Scientific by 2.2% during the first quarter. AMF Tjanstepension AB now owns 854,223 shares of the medical equipment provider’s stock worth $58,506,000 after buying an additional 18,320 shares in the last quarter. Courier Capital LLC boosted its stake in shares of Boston Scientific by 22.5% in the first quarter. Courier Capital LLC now owns 11,399 shares of the medical equipment provider’s stock valued at $781,000 after buying an additional 2,096 shares during the period. 180 Wealth Advisors LLC grew its position in Boston Scientific by 36.5% during the first quarter. 180 Wealth Advisors LLC now owns 5,621 shares of the medical equipment provider’s stock worth $385,000 after buying an additional 1,504 shares in the last quarter. Tlwm bought a new position in Boston Scientific during the 1st quarter worth $927,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Boston Scientific by 10.9% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 66,024 shares of the medical equipment provider’s stock valued at $4,522,000 after acquiring an additional 6,485 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Argus increased their target price on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. Raymond James boosted their target price on shares of Boston Scientific from $73.00 to $85.00 and gave the company a “strong-buy” rating in a research report on Thursday, April 25th. The Goldman Sachs Group began coverage on shares of Boston Scientific in a research report on Thursday, May 30th. They set a “buy” rating and a $90.00 price target on the stock. Mizuho boosted their price objective on shares of Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, May 15th. Finally, UBS Group raised their target price on Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Two research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $76.70.

Boston Scientific Trading Up 0.0 %

BSX traded up $0.01 during trading on Friday, reaching $77.01. 7,714,856 shares of the company’s stock were exchanged, compared to its average volume of 5,196,856. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a one year low of $48.35 and a one year high of $77.99. The firm has a fifty day moving average price of $74.84 and a two-hundred day moving average price of $67.51. The stock has a market capitalization of $112.98 billion, a PE ratio of 64.71, a price-to-earnings-growth ratio of 2.65 and a beta of 0.81.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.05. The company had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $75.33, for a total transaction of $526,029.39. Following the completion of the transaction, the executive vice president now owns 45,628 shares in the company, valued at approximately $3,437,157.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Arthur C. Butcher sold 14,011 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total transaction of $1,055,588.74. Following the sale, the executive vice president now owns 20,197 shares in the company, valued at approximately $1,521,641.98. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $75.33, for a total value of $526,029.39. Following the completion of the sale, the executive vice president now owns 45,628 shares of the company’s stock, valued at $3,437,157.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 81,627 shares of company stock worth $5,937,353. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.